


Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Complete if Known</b>	
		Application Number	20859
		Filing Date	February 21, 2002 with Express Mail Label No. EL912162005 US
		First Name Inventor	Brandt, M. et al.

Sheet 1 of 1

#### U.S. PATENT DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
gr	A1	5,977,310		Namiki, et al.	November 2, 1999

#### FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B1	EP	0 816 381	Duplicate for (892)		January 7, 1998	
gr	B2	WO	94/13322			June 23, 1994	
gr	B3	WO	93/23541			November 25, 1993	

#### NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
gr	C1 ✓	Date, K., et al., FEBS Letters Vol. 420 (1997) pgs. 1-6	
	C2 ✓	Date, K., et al., Oncogene (1998) Vol. 17 pgs. 3045-3054 Duplicate (892)	
gr	C3 ✓	Kuba, K., et al. Cancer Research (2000) Vol. 60, pgs. 6737-6743	
gr	C4 ✓	Uematsu Y., et al., Journal of Pharmaceutical Sciences (1/99), Vol. 88 No. 1, pgs. 131-135	
	C5 ✓	Gaertner, H., et al., Bioconjugate Chem. (1996) Vol. 7 pgs. 38-44 ) DOPPLICATE (892)	
gr	C6 ✓	Francis, G.E., et al., International Journal of Hematology, Vol. 68 (1998) pgs. 1-18	
	C7 ✓	Tsutsumi, Y. et al. Thrombosis & Haemostasis Vol. 77, No. 1 (1997) pgs. 168-173	
	C8 ✓	Tsutsumi, Y. et al., Proceedings of the National Academy of Sciences of the United States, Vol. 97, No. 15 (7/18/00) pgs. 8548-8553	
	C9 ✓	Heinzerling, L., et al., Dermatology (2000) Vol. 201, pgs. 154-157	
	C10 ✓	Tsutsumi, Y. et al., Journal of Pharmacology & Experimental Therapeutics Vol. 278 No. 3 (1996) pgs. 1006-1011	
	C11 ✓	Reddy, R., et al. Annals of Pharmacotherapy Vol. 34, No. 7-8 (7/2000) pgs. 915-923	
	C12 ✓	Bailon, P., Bioconjugate Chem. Vol. 12 (02/16/2001) pgs. 195-202	
gr	C13 ✓	Parr, C., et al., Int. J. Cancer Vol. 85 (2000) pgs. 563-570	

Examiner Signature	Lyman Charlson	Date Considered	3/10/06
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

117847